8 Best United Therapeutics Alternatives & Competitors (2026)

Organovo pioneered commercial 3D bioprinted human tissues, primarily for drug discovery and disease modeling rather than direct implantation. Its platform strengths include established manufacturing processes and partnerships with pharma for ADME/Tox testing. Compared with Trestle Biotherapeutics, Organovo has not pursued therapeutic implantation for ESRD and instead monetizes research-use tissues, resulting in different regulatory and reimbursement paths.

Humacyte develops acellular bioengineered vessels and is advancing clinical trials for vascular access in dialysis patients. Its off-the-shelf approach avoids cell sourcing complexities. Relative to Trestle, Humacyte targets immediate surgical needs rather than whole kidney replacement, offering a nearer-term but narrower solution for ESRD complications.

Miromatrix uses perfusion decellularization to create transplantable organ scaffolds, with programs in kidney and liver. Strengths include whole-organ architecture preservation. Versus Trestle Biotherapeutics, Miromatrix focuses on recellularized donor scaffolds rather than stem cell-derived de novo tissues, creating different supply chain and immunogenicity considerations.

Fresenius operates the largest dialysis clinic network and manufactures dialysis equipment worldwide. It excels at scalable chronic care delivery. In contrast to Trestle Biotherapeutics' regenerative implant goal, Fresenius optimizes existing dialysis infrastructure and has no current stem cell or bioprinting therapeutic pipeline.

CELLINK supplies bioprinting hardware, bioinks, and kidney organoid protocols mainly for research labs. Its strength is accessibility for academic and early discovery work. Unlike Trestle's therapeutic implantation focus, CELLINK products serve in vitro modeling and do not target clinical ESRD treatment directly.

DaVita runs extensive dialysis centers and emphasizes patient quality-of-life programs within the existing treatment paradigm. It has no regenerative medicine pipeline. Against Trestle Biotherapeutics, DaVita optimizes current dialysis economics and care coordination rather than developing alternatives that could reduce dialysis dependence.

Vericel commercializes autologous cell therapies for cartilage and cardiac repair with approved products and reimbursement. Its clinical and manufacturing expertise is proven. Relative to Trestle, Vericel has not entered kidney tissue engineering and its cell expansion methods differ from Trestle's biofabrication approach.